

## Appendix 13

### Drug Categories Allowing Prior Authorization Approval Through the STAT-PA System

Prior authorization (PA) requests should be submitted through the Specialized Transmission Approval Technology — PA (STAT-PA) system for the following drug categories:

- Angiotensin converting enzyme (ACE) inhibitors.
- Non-steroidal anti-inflammatory drugs (NSAIDs) that are enzyme cyclooxygenase-2 (COX-2) inhibitors.
- NSAIDs that are not enzyme COX-2 inhibitors.

The following tables also list drug categories that should be submitted through STAT-PA:

<b>Drug Category</b>	Alpha-1-Proteinase Inhibitor, Human Systemic
<b>Approval Criteria</b>	Indicated for replacement therapy in recipients with emphysema, panacinar, due to congenital alpha-1-antitrypsin deficiency (treatment).
<b>Specific Requirements</b>	None

<b>Drug Category</b>	Brand Name Histamine 2 Antagonists
<b>Approval Criteria</b>	Indicated for ulcers, duodenal, gastric, or peptic; systemic mastocytosis; multiple endocrine adenoma; gastric hypersecretory conditions; Zollinger-Ellison syndrome; erosive esophagitis; gastroesophageal reflux disease; ulcers due to H. Pylori. <ul style="list-style-type: none"> <li>• Use for these diagnoses is available through STAT-PA.</li> <li>• Use for any other diagnosis requires paper PA.</li> </ul>
<b>Specific Requirements</b>	None

<b>Drug Category</b>	Weight Loss Products
<b>Approval Criteria</b>	Indicated as adjunctive weight-loss therapy to diet and exercise.
<b>Specific Requirements</b>	Documentation of recipient's height and weight.

<b>Drug Category</b>	Stimulants, C-III and C-IV
<b>Approval Criteria</b>	Indicated as an appetite suppressant in the treatment of exogenous obesity for short-term use (a few weeks) in a regimen of weight reduction based on caloric reduction.
<b>Specific Requirements</b>	Documentation of recipient's height and weight.